Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Wu, Jianzhang ^a   Wei, Tao ^a   Tang, Qinqin ^a   Weng, Bixia ^a   Li, Wulan ^a   Jiang, Xin ^a   Ding, Ting ^b   Li, Xiaokun ^a   Liang, Guang ^a   Cai, Yuepiao ^a   Ji, Jiansong ^a,c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b LISHUI PEOPLE S HOSPITAL   (China)

^c LISHUI CENTRAL HOSPITAL   (China)

Author keywords

Anti cancer; Fibroblast growth factor receptor 1; NDGA; Non ATP competitive FGFR1 inhibitors; Non small cell lung cancer

Indexed keywords

3,5 BIS(3,4 DIHYDROXYBENZYLIDENE)TETRAHYDROPYRAN 4 ONE; 3,5 BIS(3,4 DIHYDROXYBENZYLIDENE)TETRAHYDROTHIOPYRAN 4 ONE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLOOXYGENASE 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; NORDIHYDROGUAIARETIC ACID; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME INHIBITION ASSAY; FEMALE; GEL MOBILITY SHIFT ASSAY; HEK293 CELL LINE; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; LUNG NEOPLASMS; METABOLISM; PHOSPHORYLATION; PROCEDURES; SYNTHESIS; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DISCOVERY; HUMANS; LUNG NEOPLASMS; MASOPROCOL; MICE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928323469     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1307-9     Document Type: Article

References (25)

1. Kono SA, Marshall ME, Ware KE, Heasley LE. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Updat. 2009;12(4-5):95-102.
2. Saijo N. Targeted therapies: Tyrosine-kinase inhibitors-new standard for NSCLC therapy. Nat Rev Clin Oncol. 2010;7(11):618-9.
3. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305(5687):1163-7.
4. Horn L, Sandler A. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res. 2009;15(16):5040-8.
5. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009;462(7276):1070-4.
6. Hammerman PS, Janne PA, Johnson BE. Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Clin Cancer Res. 2009;15(24):7502-9.
7. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009;9(1):28-39.
8. Liang G, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci. 2012;33(10):531-41.
9. Fang Z, Grutter C, Rauh D. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. ACS Chem Biol. 2013;8(1):58-70.
10. Kohler LH, Mireskandari M, Knosel T, Altendorf-Hofmann A, Kunze A, Schmidt A, et al. FGFR1 expression and gene copy numbers in human lung cancer. Virchows Arch. 2012;461(1):49-57.
11. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011;6(6):e20351.
12. Terai H, Soejima K, Yasuda H, Nakayama S, Hamamoto J, Arai D, et al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC. Mol Cancer Res. 2013;11(7):759-67.
13. Tran TN, Selinger CI, Kohonen-Corish MR, McCaughan BC, Kennedy CW, O'Toole SA, et al. Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer. Lung Cancer. 2013;81(3):462-7.
14. Preusser M, Berghoff AS, Berger W, Ilhan-Mutlu A, Dinhof C, Widhalm G, et al. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer. Lung Cancer. 2014;83(1):83-9.
15. Heist RS, Mino-Kenudson M, Sequist LV, Tammireddy S, Morrissey L, Christiani DC, et al. FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol. 2012;7(12):1775-80.
16. Yang J, Zhao H, Xin Y, Fan L. MicroRNA-198 inhibits proliferation and induces apoptosis of lung cancer cells via targeting FGFR1. J Cell Biochem. 2013. doi:10.1002/jcb.24742.
17. Zhang J, Zhang L, Su X, Li M, Xie L, Malchers F, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res. 2012;18(24):6658-67.
18. Meyer AN, McAndrew CW, Donoghue DJ. Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells. Cancer Res. 2008;68(18):7362-70.
19. Krejci P, Murakami S, Prochazkova J, Trantirek L, Chlebova K, Ouyang Z, et al. NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. J Biol Chem. 2010;285(27):20644-53.
20. Eathiraj S, Palma R, Hirschi M, Volckova E, Nakuci E, Castro J, et al. A novel mode of protein kinase inhibition exploiting hydrophobic motifs of autoinhibited kinases: discovery of ATP-independent inhibitors of fibroblast growth factor receptor. J Biol Chem. 2011;286(23):20677-87.
21. Wang Y, Cai Y, Ji J, Liu Z, Zhao C, Zhao Y, et al. Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer. Cancer Lett. 2014;344:82-9.
22. Wu J, Li J, Cai Y, Pan Y, Ye F, Zhang Y, et al. Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. J Med Chem. 2011;54(23):8110-23.
23. Lu JM, Nurko J, Weakley SM, Jiang J, Kougias P, Lin PH, et al. Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update. Med Sci Monit. 2010;16(5):RA93-100.
24. Ren M, Hong M, Liu G, Wang H, Patel V, Biddinger P, et al. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep. 2013;29(6):2181-90.
25. Liang G, Chen G, Wei X, Zhao Y, Li X. Small molecule inhibition of fibroblast growth factor receptors in cancer. Cyto Growth Factor Rev. 2013;24(5):467-75.